APA (7th ed.) Citation

B, P., MF, J., M, P., E, T., A, K., I, L., . . . CC, S. (2026). Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML. Blood, 147(3), 276. https://doi.org/10.1182/blood.2025030558

Chicago Style (17th ed.) Citation

B, Popescu, et al. "Multiselective RAS(ON) Inhibition Targets Oncogenic RAS and Overcomes RAS-mediated Resistance to FLT3i and BCL2i in AML." Blood 147, no. 3 (2026): 276. https://doi.org/10.1182/blood.2025030558.

MLA (9th ed.) Citation

B, Popescu, et al. "Multiselective RAS(ON) Inhibition Targets Oncogenic RAS and Overcomes RAS-mediated Resistance to FLT3i and BCL2i in AML." Blood, vol. 147, no. 3, 2026, p. 276, https://doi.org/10.1182/blood.2025030558.